한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제27권4호
  • /
  • Pages.207-213
  • /
  • 2017
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지
DOI QR코드

DOI QR Code

기계환기관련 폐렴치료 시 Aerosolized Colistin의 효과 및 안전성에 대한 체계적 문헌 고찰 및 메타분석

Efficacy and Safety of Aerosolized Colistin in the Treatment of Ventilator-Associated Pneumonia: A Systematic Review and Meta-analysis

  • 백민우 (중앙대학교 약학대학, 사회보건임상약학대학원, 근거기반 약물치료학 연구실) ;
  • 정경혜 (중앙대학교 약학대학) ;
  • 김은영 (중앙대학교 약학대학, 사회보건임상약학대학원, 근거기반 약물치료학 연구실)
  • Paik, Minwoo (Evidence based research Lab, Social, health, and clinical pharmacy department, College of Pharmacy, Chung-Ang University) ;
  • Jeung, Kyeonghye (College of Pharmacy, Chung-Ang University) ;
  • Kim, Eun Young (Evidence based research Lab, Social, health, and clinical pharmacy department, College of Pharmacy, Chung-Ang University)
  • 투고 : 2017.08.19
  • 심사 : 2017.12.15
  • 발행 : 2017.12.29
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: It is recommended to use aerosolized (AS) colistin in patients undergoing mechanical ventilation therapy as an adjunctive in the latest guidelines, in spite of high nephrotoxicity and limited studies. In this study, systematic reviews and meta-analyzes were conducted to evaluate the safety and efficacy of AS colistin in patients with ventilator-associated pneumonia Methods: Two authors independently searched related literature published from Pubmed and EMBASE until July 2016 and included a study comparing adjunctive AS colistin with intravenous (IV) colistin monotherapy. The primary outcome was the clinical response rate, the secondary outcome was the overall mortality, and nephrotoxicity. The publication bias was evaluated using the Egger's test. Results: Of the total 279 articles, nine were finally included in the final analysis. There was a significant difference between the adjunctive AS colistin group and the IV colistin monotherapy group for the treatment-response rate (odds ratio (OR), 1.56; 95% CI, 1.14-2.14; p = 0.005; $I^2=36%$), although there was no significant difference in overall mortality (OR, 0.77; 95% CI, 0.57-1.04; p = 0.09; $I^2=20%$). However, there was no significant difference between the two groups in nephrotoxicity (OR, 1.13; 95% CI, 0.74-1.74; p = 0.57; $I^2=4%$). Conclusion: The addition of aerosolized colistin to IV colistin monotherapy showed better results in terms of efficacy than IV colistin monotherapy and did not show any significant difference in terms of total mortality and nephrotoxicity. Additional large-scale studies of this need to be verified.

키워드

참고문헌

  1. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274(8):639-44. https://doi.org/10.1001/jama.1995.03530080055041
  2. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. CHEST 2002;122(6):2115-21. https://doi.org/10.1378/chest.122.6.2115
  3. Kollef KE, Schramm GE, Wills AR, et al. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. CHEST 2008;134(2):281-7. https://doi.org/10.1378/chest.08-1116
  4. Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 2013;13(8):665-71. https://doi.org/10.1016/S1473-3099(13)70081-1
  5. Siempos, II, Vardakas KZ, Kyriakopoulos CE, et al. Predictors of mortality in adult patients with ventilator-associated pneumonia: a metaanalysis. Shock (Augusta, Ga) 2010;33(6):590-601. https://doi.org/10.1097/SHK.0b013e3181cc0418
  6. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013;34(1):1-14. https://doi.org/10.1086/668770
  7. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis: an official publication of the Infectious Diseases Society of America 2010;51 Suppl 1:S81-7. https://doi.org/10.1086/653053
  8. Ling LL, Schneider T, Peoples AJ, et al. A new antibiotic kills pathogens without detectable resistance. Nature 2015;517(7535):455-59. https://doi.org/10.1038/nature14098
  9. Chemical Sciences R, Board on Chemical S, Technology, et al. The National Academies Collection: Reports funded by National Institutes of Health. Technological Challenges in Antibiotic Discovery and Development: A Workshop Summary. Washington (DC): National Academies Press (US)Copyright 2014 by the National Academy of Sciences. All rights reserved. 2014.
  10. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009;64 (suppl 1):i29-36. https://doi.org/10.1093/jac/dkp255
  11. Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. CHEST 2010;138(6):1333-9. https://doi.org/10.1378/chest.10-0463
  12. Ratjen F, Rietschel E, Kasel D, et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006;7(2):306-11.
  13. Palmer LB, Smaldone GC, Simon SR, et al. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 1998;26(1):31-9. https://doi.org/10.1097/00003246-199801000-00013
  14. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis: an official publication of the Infectious Diseases Society of America 2016;63(5):e61-e111. https://doi.org/10.1093/cid/ciw353
  15. Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med 2015;43(3):527-33. https://doi.org/10.1097/CCM.0000000000000771
  16. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
  17. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1. 0 [updated March 2011] 2011: Oxford: The Cochrane Collaboration, 2015.
  18. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6(9):589-601. https://doi.org/10.1016/S1473-3099(06)70580-1
  19. Nation RL, Li J. Colistin in the 21st century. Current opinion in infectious diseases 2009;22(6):535-43. https://doi.org/10.1097/QCO.0b013e328332e672
  20. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) 2003;327(7414):557-60. https://doi.org/10.1136/bmj.327.7414.557
  21. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed) 1997;315(7109):629-34. https://doi.org/10.1136/bmj.315.7109.629
  22. Doshi NM, Cook CH, Mount KL, et al. Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study. BMC anesthesiology 2013;13(1):45. https://doi.org/10.1186/1471-2253-13-45
  23. Kalin G, Alp E, Coskun R, et al. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infect Chemother: official journal of the Japan Society of Chemotherapy 2012;18(6):872-7. https://doi.org/10.1007/s10156-012-0430-7
  24. Kofteridis DP, Alexopoulou C, Valachis A, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis: an official publication of the Infectious Diseases Society of America 2010;51(11):1238-44. https://doi.org/10.1086/657242
  25. Korbila IP, Michalopoulos A, Rafailidis PI, et al. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2010;16(8):1230-6. https://doi.org/10.1111/j.1469-0691.2009.03040.x
  26. Naesens R, Vlieghe E, Verbrugghe W, et al. A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa. BMC infectious diseases 2011;11:317. https://doi.org/10.1186/1471-2334-11-317
  27. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010;65(12):2645-9. https://doi.org/10.1093/jac/dkq360
  28. Tumbarello M, De Pascale G, Trecarichi EM, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistinonly susceptible gram-negative bacteria. CHEST 2013;144(6):1768-75. https://doi.org/10.1378/chest.13-1018
  29. Polat M, Kara SS, Tapisiz A, et al. Treatment of Ventilator-Associated Pneumonia Using Intravenous Colistin Alone or in Combination with Inhaled Colistin in Critically Ill Children. Paediatr Drugs 2015;17(4):323-30. https://doi.org/10.1007/s40272-015-0133-5
  30. Demirdal T, Sari US, Nemli SA. Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii? Ann Clin Microbiol Antimicrob 2016;15:11. https://doi.org/10.1186/s12941-016-0123-7
  31. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171(4):388-416. https://doi.org/10.1164/rccm.200405-644ST
  32. Perez-Pedrero M, Sanchez-Casado M, Rodriguez-Villar S. Nebulized colistin treatment of multi-resistant Acinetobacter baumannii pulmonary infection in critical ill patients. Med Intensiva (English Edition) 2011;35(4):226-31. https://doi.org/10.1016/S2173-5727(11)70029-7